Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bullish +45

Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings

📈 Guggenheim raised its price target on Amgen Inc. (AMGN) from $347 to $351, citing an updated financial model ahead of earnings.

⚖️ The firm maintains a Neutral rating on AMGN while acknowledging the stock's potential as an undervalued Dow component.

📊 First-quarter results are expected to be released after market close on April 30, following Guggenheim's model update.

💉 Amgen announced positive Phase 3 trial results for TEPEZZA in patients with moderate-to-severe active thyroid eye disease on April 6.

🎯 The trial achieved its primary endpoint with a 77% proptosis response rate compared to 19.6% for placebo over 24 weeks.

👁️ Patients using the new subcutaneous injector showed an average mean eye bulge reduction of -3.17 mm versus -0.80 mm for placebo.

🔬 Secondary endpoints were also met, including improvements in diplopia outcomes, disease activity scores, and quality-of-life measures.

⚕️ Safety findings were consistent with the known intravenous formulation profile, featuring mainly mild-to-moderate injection site reactions.

➡️ The subcutaneous delivery system offers a more convenient administration option compared to the established intravenous formulation.

🏢 Amgen is a leading global biotechnology company focused on oncology, cardiovascular disease, inflammation, bone health, and rare diseases.

⚠️ Some analysts suggest AI stocks offer greater upside potential with less downside risk compared to AMGN currently.

📰 TheFly reported the analyst action and trial results as part of broader coverage on biotech and undervalued stocks.

Bullish Signals
  • Guggenheim increased Amgen's price target from $347 to $351, reflecting updated optimism ahead of the company's first-quarter earnings expected after market close on April 30.
  • Amgen announced positive Phase 3 results for TEPEZZA using a subcutaneous on-body injector, achieving its primary endpoint with a 77% proptosis response rate versus 19.6% for placebo over 24 weeks.
  • The clinical trial for TEPEZZA demonstrated significant improvements in diplopia outcomes, disease activity scores, quality-of-life measures, and overall responder rates with statistically significant benefits.
  • The subcutaneous delivery system offered a more convenient administration option while maintaining strong clinical performance comparable to the established IV formulation.
  • Amgen's safety profile remained consistent with mild-to-moderate injection site reactions and no treatment discontinuations, indicating favorable risk management for this therapy.
  • As a leading global biotechnology company, Amgen continues to innovate in oncology, cardiovascular disease, inflammation, bone health, and rare diseases using advanced biologics and genetic science.
Risk Factors
  • Guggenheim maintained a Neutral rating on Amgen Inc. (AMGN) despite increasing the price target, indicating uncertainty about future upside potential.
  • The firm is updating its financial model ahead of first-quarter results expected after market close on April 30, suggesting that upcoming earnings could introduce volatility or disappointment.
  • Analysts argue that certain AI stocks offer greater upside potential and carry less downside risk compared to AMGN, reflecting competitive concerns in the investment landscape.
  • There are no significant risks explicitly highlighted beyond analyst preference for AI exposure over biotech investments at present.
Full Analysis
Guggenheim adjusted its price target on Amgen Inc. (NASDAQ: AMGN) from $347 to $351, citing updates to its financial model ahead of the biotechnology company's first-quarter earnings expected after market close on April 30. The brokerage maintained a Neutral rating on the stock, while noting in their analysis that Amgen remains among the most undervalued Dow stocks currently available for investment. This valuation adjustment occurs alongside recent clinical progress for the company's new therapy. Amgen recently announced positive topline Phase 3 results for TEPEZZA, an investigational drug delivered via a subcutaneous on-body injector for patients with moderate-to-severe active thyroid eye disease. The study achieved its primary endpoint, demonstrating a 77% proptosis response rate compared to 19.6% for placebo over 24 weeks, with a mean eye bulge reduction of -3.17 mm versus -0.80 mm for the placebo group. The trial also met secondary endpoints related to improvements in diplopia outcomes, disease activity scores, quality-of-life measures, and overall responder rates, while safety findings remained consistent with the known intravenous formulation profile featuring mainly mild-to-moderate injection site reactions. Amgen describes itself as a leading global biotechnology company specializing in innovative human therapeutics for oncology, cardiovascular disease, inflammation, bone health, and rare diseases using advanced biologics and genetic science. The recent positive clinical data suggests a potential new administration option for a condition that can significantly impair vision and daily functioning. However, Guggenheim notes in its commentary that while it acknowledges the investment potential of AMGN, it believes certain AI stocks offer greater upside potential with less downside risk, pointing investors toward a free report on undervalued AI stocks benefiting from onshoring trends instead.